Italian Sarcoma Group

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.italiansarcomagroup.org/

Clinical Trials

Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)

Phase 1

Completed

Conditions: Bone Tumor
Soft Tissue Sarcoma

Interventions: Drug: trabectedin
Drug: olaparib

First Posted Date: 2015-03-25

Last Posted Date: 2021-04-14

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 50

Registration Number: NCT02398058

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
🇮🇹
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy
🇮🇹
Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, Italy

Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma

Phase 2

Completed

Conditions: Leiomyosarcoma
Liposarcoma

Interventions: Drug: Trabectedin

First Posted Date: 2014-09-25

Last Posted Date: 2021-11-01

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 105

Registration Number: NCT02247544

Locations: 🇮🇹
Azienda Ospedaliera Sant'Anna, Como, CO, Italy
🇮🇹
IRST IRCCS Meldola, Meldola, FC, Italy
🇮🇹
A.O. Spedali Civili, Brescia, BS, Italy

and more 18 locations

Trabectedin First Line Therapy In Unfit Sarcoma Study

Phase 2

Completed

Conditions: Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive
Standard Chemotherapy

Interventions: Drug: Trabectedin

First Posted Date: 2014-02-19

Last Posted Date: 2018-04-11

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 24

Registration Number: NCT02066675

Locations: 🇮🇹
Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
🇮🇹
Ospedale Galliera, Genova, Genovs, Italy
🇮🇹
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy

and more 13 locations

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

Phase 3

Completed

Conditions: Ewing's Sarcoma

Interventions: Drug: Standard treatment (as per protocol ISG SSG III)
Drug: Intensified chemotherapy

First Posted Date: 2014-02-14

Last Posted Date: 2022-09-19

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 278

Registration Number: NCT02063022

Locations: 🇮🇹
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
🇮🇹
Azienda Ospedaliera Universitaria "Federico Ii" ., Napoli, Italy
🇮🇹
Centro di Riferimento Oncologico - Unit of Medical Oncology, Aviano, Pordenone, Italy

and more 11 locations

Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma

Phase 2

Completed

Conditions: Relapsed Osteosarcoma
Metastatic Osteosarcoma

Interventions: Drug: Sorafenib
Drug: Everolimus

First Posted Date: 2013-03-05

Last Posted Date: 2015-06-17

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 38

Registration Number: NCT01804374

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Phase 3

Active, not recruiting

Conditions: Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

Interventions: Drug: gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)
Drug: epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)
Drug: trabectedin 1.3 mg/m2
Drug: high-dose ifosfamide 14 g/m2, given in in 14 days
Drug: etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)
Drug: gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)

First Posted Date: 2012-10-19

Last Posted Date: 2023-09-13

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 550

Registration Number: NCT01710176

Locations: 🇪🇸
Hospital Son Espases, Palma de Mallorca, Spain
🇪🇸
Hospital Vall D'Hebron, Barcelona, Spain
🇪🇸
Hospital Clínico de Malaga, Malaga, Spain

and more 12 locations

ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

Phase 2

Completed

Conditions: Osteosarcoma

Interventions: Drug: Mifamurtide arm
Other: 3 drugs arm

First Posted Date: 2011-10-25

Last Posted Date: 2024-05-20

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 225

Registration Number: NCT01459484

Locations: 🇮🇹
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
🇮🇹
A.O. Universitaria Meyer, Firenze, Italy
🇮🇹
FONDAZIONE IRCCS Istituto Nazionale dei Tumori, Milano, Italy

and more 8 locations

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Phase 2

Completed

Conditions: Advanced Desmoid Tumor
Advanced Chondrosarcoma

Interventions: Drug: Imatinib Mesylate

First Posted Date: 2009-06-26

Last Posted Date: 2023-10-05

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 35

Registration Number: NCT00928525

Locations: 🇮🇹
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
🇮🇹
Centro di Riferimento Oncologico - Unit of Medical Oncology, Aviano, Pordenone, Italy
🇮🇹
Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I, Roma, Italy

and more 4 locations

Sorafenib in Relapsed High Grade Osteosarcoma

Phase 2

Completed

Conditions: Osteosarcoma

Interventions: Drug: sorafenib

First Posted Date: 2009-04-28

Last Posted Date: 2013-03-28

Lead Sponsor: Italian Sarcoma Group

Target Recruit Count: 35

Registration Number: NCT00889057

Locations: 🇮🇹
Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, Italy
🇮🇹
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
🇮🇹
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy